Latin America and Sub-Saharan Africa
This report aims to distinguish some comparable differences in problems between Latin America and Sub-Saharan Africa. The report incorporates the findings of three articles on immigration, environmental concerns and family planning. The report aims to discuss how these areas of concern are being addressed and how they have been or may be solved. From there, the objective is to forecast some possible solutions for these serious long-term issues that are all too apparent throughout many of the African continent.
People are the true source of success. Therefore, when the best people in a country or region leave to find a better way of life abroad through education or other opportunities, they inadvertently have some effect on the country they left behind. "For example, the number of immigrants from Spanish-speaking Latin America increased by...
In contrast, the number of immigrants from Europe increased by less than 700,000 and those from Sub-Saharan Africa increased by about 400,000." (Camarota and McArdle) This seems to be more of dilemma in Africa than in Latin America because a great number of Latin immigration is to the United States where an immigrant can most likely find better sources of jobs and a better way of life. With that comes the ability to provide financial assistance to family's back home. Migration from Africa usually entails only the best and the brightest who make their way to universities around the world. These opportunities often do not lead to financial assistance back home. But more important, it also means that the newly educated person who may now be a doctor or lawyer will not return to his home country again affecting the overall success…
Weight and Obesity The Prevalence of Overweight and Obesity in Immigrant Women from Sub-Saharan Africa Living in Grande Prairie, Alberta In spite of the increased prevalence of overweight and obesity in the general population, little attention has been paid to immigrant communities, which are at a greater risk of weight gain compared to the majority. This is quite disturbing given the increased rate of migration from low-income countries. Lack of epidemiological data
In the 21st century, American, European, and Asian trans-national corporations (e.g., General Motors; Toyota; Coca Cola; IBM; Nestle, etc., build plants in Mexico and Latin America, where indigenous labor is cheaper than American labor. Meanwhile, tens of thousands of poor Mexican citizens living in poverty struggle to sneak across the borders of the United States, into California, Arizona, Texas, or New Mexico, in hope of finding better lives by
This region had long been the source of slaves for the route through the Sahara to the Mediterranean. The arrival of the Portuguese opened up another channel which they expanded during the 16th century. On the east coast the Portuguese were drawn to Mozambique and the Zambezi River by news of a local people, the Munhumutapa, who allegedly possessed fabulous wealth in gold. In 1531, in an effort to reach
It produced a net increase in perceived benefits of protective behavior and in self-efficacy among both males and females, and a reduction in perceived barriers to protective behavior among females. Consistent with these changes, it was also associated with a reduction in risky sexual behavior among young men and an increase in contraceptive use among young men and women (Agha, 2002, p. 67+). Agha also noted that there was more
-- but Glaxo contends that Cipla violates the companies' patents and international intellectual- property agreements"(Boseley, 2002). In moral defense of its actions, Glaxo's CEO, told shareholders "Some people might see patents as the obstacle to getting medicines to patients in poorer countries. Nothing could be further from the truth....Even in countries where low cost generics are available millions of people are dying every year because they cannot obtain low
Genzyme is a leader in the biotechnology industry, and established its reputation as early as 1981 by supplying the market with certain chemicals. The company attributes its success to its focus on rather rare or "orphan" diseases and the development of drugs that capture market share for those ailments. However, there are two sides to this issue. The research and development process for these rarer drugs is tremendously expensive, resulting